Skip to main content
OpenTrials
Completed

NCT Number: NCT01947478

MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery

The purpose of this trial is to assess the safety and efficacy of MDT-2113 for the interventional treatment of de novo and non-stented restenotic lesions in the superficial femoral artery (SFA) and the proximal popliteal artery (PPA) as compared to treatment with standard percutaneous transluminal angioplasty (PTA).

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kansai Rosai Hospital

Amagasaki, Hyōgo, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: ≥ 20 years and ≤ 85 years
  • Documented ischemia with Rutherford classification 2, 3, or 4
  • Able to walk without assistive devices
  • Target lesion is in the SFA and/or PPA above the knee
  • Target lesion consists of a single de novo or non-stented restenotic lesion (or tandem lesions) or is a combination lesion that meets the following criteria:
  • ≥ 70% and < 100% occluded with total lesion length ≥ 40 mm and ≤ 200 mm
  • 100% occluded with total lesion length ≤100 mm
  • Combination lesions must have total lesion length ≥40 mm and ≤200 mm with an occluded segment that is ≤ 100 mm in length (by visual estimates)
  • Reference vessel diameter ≥ 4 mm and ≤7 mm (by visual estimate)
  • Angiographic evidence of adequate distal run-off through the foot

Exclusion criteria

  • Stroke or STEMI within the 3 months prior to enrollment
  • Either local or systemic thrombolytic therapy within the 48 hours prior to the index procedure
  • Inability to tolerate oral anticoagulation therapy (blood thinners such as warfarin) while on concomitant dual antiplatelet therapy (DAPT)
  • Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant/antiplatelet therapies or to paclitaxel, or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure
  • Chronic renal insufficiency
  • Subject is enrolled in another investigational device, drug, or biologic study
  • Any major surgical procedure or intervention performed within the 30-day period prior to or post index procedure
  • Contralateral SFA/PPA disease requiring treatment in the same setting as index procedure
  • Failure to successfully cross the target lesion
  • Angiographic evidence of severe calcification
  • Target lesion known in advance of enrollment to require treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices, cutting balloons, scoring balloons; use of embolic protection devices is also prohibited

Treatment and study plan

MDT-2113 Drug-Eluting Balloon

Device

Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm

Standard angioplasty balloon

Device

Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm

Primary outcomes

  1. Efficacy: Primary patency

    Time frame: 12 month

    Primary patency is defined as freedom from clinically-driven target lesion revascularization (TLR) and freedom from restenosis as determined by duplex ultrasound (DUS)

Secondary outcomes

  1. Primary safety endpoint

    Time frame: 12 month

    Freedom from device- and procedure-related death through 30 days post-procedure, and freedom from target limb major amputation and clinically-driven target vessel revascularization (TVR)

Sponsors and collaborators

Lead sponsor

Medtronic Endovascular

Industry

Registry information

Official study title

Randomized Trial of MDT-2113 Drug-Eluting Balloon (DEB) vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery

Acronym: MDT-2113 SFA

Important dates

Study start
2013
Primary completion
2018
Study completion
2018
First posted
Sep 20, 2013
Registry last updated
Jan 31, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.